Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Six-Year Study Will Compare Bayer’s Essure With Tubal Ligation

Executive Summary

US FDA has accepted a post-approval study plan by Bayer HealthCare for its Essure permanent sterilization device, which is under intense scrutiny in response to adverse events and charges of clinical trial misconduct. The protocol entails a non-randomized, six-year cohort study comparing Essure-implanted women to tubal ligation sterilization subjects.


Related Content

Bayer Halts Essure Sales In EU As US FDA Relies On Study, Patient Warnings
FDA Says Bayer's Response To Essure Investigation Satisfactory; Approves Product Label
US House Members Urge Hearings On Device Safety
Reps. Fitzpatrick, Slaughter Introduce Device Defect Reform Bills
Pennsylvania Lawmaker Wants Power Morcellators Reviewed In Cancer 'Moonshot' Initiative
FDA Essure Actions Draw Lawmaker Ire, Demand For Product Withdrawal
FDA Investigating Attorney, Physician Beefs With Bayer’s Essure PMA
Essure Panel Stresses Need For Patient Follow-Up, But Stressed-Out Patients Say, ‘Recall It’


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts